Stem Cell Transplantation in Scleroderma Therapy

dc.contributor.author	Ali, Buthaina Ahmed
dc.date.accessioned	2019-04-20T10:28:57Z
dc.date.available	2019-04-20T10:28:57Z
dc.date.issued	2018-04-13
dc.identifier.uri	http://repository.limu.edu.ly/handle/123456789/693
dc.description	stem cell transplant A procedure in which a patient receives healthy bloodforming cells (stem cells) to replace their own that have been destroyed by disease or by the radiation or high doses of anticancer drugs that are given as part of the procedure. The healthy stem cells may come from the blood or bone marrow of the patient, from a donor, or from the umbilical cord blood of a newborn baby. A stem cell transplant may be autologous (using a patient’s own stem cells that were collected and saved before treatment), allogeneic (using stem cells donated by someone who is not an identical twin), or syngeneic (using stem cells donated by an identical twin	en_US
dc.description.abstract	The new studies on Scleroderma therebyare Support for using hematopoietic stem cell therapy (HSCT) for SSc , which shows that stem cell transplants can provide better long-term benefits than the standard treatment for patients with severe scleroderma.	en_US
dc.language.iso	en	en_US
dc.publisher	faculty of Basic Medical Science - Libyan International Medical University	en_US
dc.rights	Attribution 3.0 United States	*
dc.rights.uri	http://creativecommons.org/licenses/by/3.0/us/	*
dc.title	Stem Cell Transplantation in Scleroderma Therapy	en_US
dc.type	Other	en_US

Except where otherwise noted, this item's license is described as Attribution 3.0 United States